Genmab A/S (0MGB) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Genmab A/S DKK 2,495, price DKK 2,269, upside +10.0%, quality 80 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
Genmab A/S
0MGB · LSEQuality WatchlistQuality growthA strong company, but the current price is close to Fair Value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range kr 1,169 – kr 3,295 · fair‑value band kr 1,328 – kr 4,407 · the kr 2,269 price screens below the kr 2,495 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Show more
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Stock analysis
Genmab A/S (0MGB) currently trades at kr 2,269, while our model-based Fair Value estimate is kr 2,495, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 3,390 per share, and 7 of the 23 models we run sit above the kr 2,269 price.
Bear case: the Economic Profit group reads lowest at kr 680.03, and 16 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 1,328 (bear) to kr 4,407 (bull), the price of kr 2,269 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genmab A/S reported revenue of 10.1B DKK in FY2020 versus 1.8B DKK in FY2016, a compound +53.6%/yr. Reported net income was 4.8B DKK in FY2020, compounding +41.5%/yr from FY2016.
Key figures
Market cap 148B DKK (≈ $22.3B) · P/S ratio 37.9 · Net margin 47.1% · Return on equity 15.0% · Return on assets (EBIT) 20.8% · Operating margin 25.1% · Revenue (TTM) 3.9B DKK · Revenue growth (YoY) +25.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, 0MGB screens cheaper than that median.
Fair Value models
All 23 models by family
Notify me when 0MGB reaches fair value
Put 0MGB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Of which business quality 80 · Market factors (momentum, volatility) 67
Revenue & earnings trend
Watch 0MGB, get fair value alerts →
Compare Genmab A/S with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Genmab A/S (0MGB) overvalued or undervalued?
What is the fair value of 0MGB?
What is the quality score of 0MGB?
What is the price target for Genmab A/S (0MGB)?
What is the Genmab A/S stock forecast for 2026?
What is the revenue of Genmab A/S (0MGB)?
What is the intrinsic value of Genmab A/S (0MGB)?
Is Genmab A/S stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 0MGB?
How much is Genmab A/S worth?
What do the bullish and bearish scenarios say about 0MGB?
How solid is the balance sheet of Genmab A/S (0MGB)?
How far is 0MGB from its 52-week high?
Which stocks are comparable to Genmab A/S?
Is Genmab A/S stock attractive at the current price?
How is the fair value of 0MGB calculated?
Is it still worth investing in stocks now?
What is the share price of Genmab A/S (0MGB)?
What should I pay attention to with Genmab A/S right now?
Key figures of Genmab A/S
How large is the market capitalisation of Genmab A/S (0MGB)?
What is the P/S ratio of Genmab A/S (0MGB)?
What is the net margin of Genmab A/S (0MGB)?
What is the return on equity of Genmab A/S (0MGB)?
What is the EBIT return on assets of Genmab A/S (0MGB)?
What is the operating margin of Genmab A/S (0MGB)?
How fast is revenue growing at Genmab A/S (0MGB)?
How fast are earnings growing at Genmab A/S (0MGB)?
Watch Genmab A/S in the live analysis
One click puts Genmab A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.